Page 93 - Clinical Olfactory Working Group Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical olfactory working group consensus statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Olfactory Working Group Consensus Statement Today - Breaking & Trending Today

NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application


(2)
SHELTON, CT / ACCESSWIRE / March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the Company ), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its two COVID-19 clinical drug candidates in an animal model of coronavirus infection.
The Company is preparing a pre-IND application encompassing its two clinical drug candidates for the treatment of COVID-19 infected patients. Of these, NV-CoV-2 is the Company s broad-spectrum anti-coronavirus drug candidate based on its nanoviricides® platform that is expected to be capable of attacking most, if not all, SARS-CoV-2 variants and other coronaviruses. In addition, the Company is also developing NV-CoV-2-R that combines (1) the power of NV-CoV-2 to attack and potentially dismantle the virus particles outside cells, and (2) the power of remdesivir to block further production of virus particles inside cells. Blockin ....

United States , Dan Vergano , Anthony Fauci , Remdesivir Veklury , Exchange Commission , Committee For Medicinal Products Human , Nanoviricides Inc , Theracour Pharma Inc , European Medicines Agency , Drug Administration , Securities Exchange , Buzzfeed News , Better Surrogate Virus , Mol Med , Human Immunodeficiency Virus , Hepatitisb Virus , Hepatitisc Virus , Herpes Simplex Virus , Varicella Zoster Virus , Asian Bird Flu Virus , Japanese Encephalitis , West Nile Virus , Theracour Pharma , Securities Act , Securities Exchange Act , United States Securities ,

Largest Alternative Treatment Plant in Europe now open with clinical waste processing capacity


Mar 09 2021 Read 600 Times
New environmentally friendly facility adds clinical waste processing capacity to support the NHS and other healthcare providers through the COVID-19 crisis while protecting people, promoting health and safeguarding the environment.
Stericycle UK, a leading provider of clinical waste and secure information destruction services, today announced it has opened an alternative treatment plant in Telford, Shropshire, to process clinical waste generated in the United Kingdom, including testing materials, sharps, hospital waste, and, in some cases, personal protective equipment (PPE) created by the COVID-19 pandemic. 
Stericycle UK processes clinical waste collected from NHS trusts and other hospitals, pharmacies, care homes, dental practices and laboratories across the U.K.  The new Telford plant, staffed by over 60 people, will increase the speed, efficiency and sustainability of this processing by using the latest technologies to steam-treat cli ....

United Kingdom , Simon Clarke , James Cardwell Moore , Birmingham Hospitals Alliance , Procurement Services , Stericycle United Kingdom , Shared Procurement Services , Co Vid , ஒன்றுபட்டது கிஂக்டம் , சிமோன் கிளார்க் , ஜேம்ஸ் அட்டை மூர் , பர்மிங்காம் மருத்துவமனைகள் கூட்டணி , ப்ரொக்யூர்மெஂட் சேவைகள் , ஸ்டெர்சைக்கிள் ஒன்றுபட்டது கிஂக்டம் , பகிரப்பட்டது ப்ரொக்யூர்மெஂட் சேவைகள் , இணை வித் ,

Welcome To IANS Live - LatestNews - Quicker decrease in Covid infection treated with Molnupiravir


Photo Credit: IANS
IANSLive
New Delhi, March 6 (IANS) Merck and Ridgeback Biotherapeutics, LP on Saturday announced preliminary results from Ridgebacks Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of Molnupiravir, an investigational oral antiviral agent.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 06-March-2021 ....

New Delhi , Ridgeback Biotherapeutics , News Service , India Private , Ridgebacks Phase , All Rights , Medi Cal , புதியது டெல்ஹி , செய்தி சேவை , இந்தியா ப்ரைவேட் , ரிட்ஜ்பேக்குகள் கட்டம் , அனைத்தும் உரிமைகள் , மேதி கலோரி ,

Welcome To IANS Live - NATION - Quicker decrease in Covid infection treated with Molnupiravir


Photo Credit: IANS
IANSLive
New Delhi, March 6 (IANS) Merck and Ridgeback Biotherapeutics, LP on Saturday announced preliminary results from Ridgebacks Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of Molnupiravir, an investigational oral antiviral agent.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 06-March-2021 ....

New Delhi , Ridgeback Biotherapeutics , News Service , India Private , Ridgebacks Phase , All Rights , Medi Cal , புதியது டெல்ஹி , செய்தி சேவை , இந்தியா ப்ரைவேட் , ரிட்ஜ்பேக்குகள் கட்டம் , அனைத்தும் உரிமைகள் , மேதி கலோரி ,